• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

作者信息

Pezzolo Elena, Narcisi Alessandra, Gargiulo Luigi, Di Lernia Vito, Napolitano Maddalena, Patruno Cataldo, Ribero Simone, Ortoncelli Michela, Foti Caterina, Romita Paolo, Gurioli Carlotta, Schena Donatella, Ferrucci Silvia Mariel, Barei Francesca, Amoruso Giuseppe Fabrizio, Russo Filomena, Naldi Luigi

机构信息

Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.

Dermatology Unit, Scientific Institute for Research, Hospitalization and Healthcare Humanitas Research Hospital, Milan, Italy.

出版信息

J Am Acad Dermatol. 2024 Nov;91(5):e147-e150. doi: 10.1016/j.jaad.2024.06.094. Epub 2024 Jul 23.

DOI:10.1016/j.jaad.2024.06.094
PMID:39047985
Abstract
摘要

相似文献

1
Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.乌帕替尼对结节性痒疹及以结节性痒疹为主型的特应性皮炎患者的有效反应：一项多中心病例系列研究
J Am Acad Dermatol. 2024 Nov;91(5):e147-e150. doi: 10.1016/j.jaad.2024.06.094. Epub 2024 Jul 23.
2
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.尼莫利珠单抗：一种创新性的生物制剂，用于控制白细胞介素 31，这是特应性皮炎和结节性痒疹的关键介质。
Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.
3
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.结节性痒疹中使用度普利尤单抗：当前证据的系统评价及应答预测因素分析。
J Dermatolog Treat. 2022 May;33(3):1547-1553. doi: 10.1080/09546634.2020.1853024. Epub 2020 Dec 3.
4
Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.曲罗芦单抗在结节性痒疹样表型特应性皮炎患者中显示出临床改善：一项多中心、前瞻性、开放标签病例系列研究。
J Am Acad Dermatol. 2023 Aug;89(2):430-432. doi: 10.1016/j.jaad.2023.04.056. Epub 2023 May 5.
5
A Case of Linear Exacerbation of Atopic Dermatitis with Secondary Prurigo Nodularis.一例特应性皮炎伴继发性结节性痒疹的线性加重病例。
Ann Dermatol. 2022 Aug;34(4):297-300. doi: 10.5021/ad.20.072.
6
[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].三例患有难治性结节性痒疹的特应性皮炎儿童
Arerugi. 2020;69(3):213-217. doi: 10.15036/arerugi.69.213.
7
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.人源单克隆抑瘤素M受体β抗体维卡瑞单抗治疗中度至重度结节性痒疹的疗效和安全性：一项随机、双盲、安慰剂对照的2a期研究
EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar.
8
Tofacitinib for Prurigo Nodularis: A Case Report.托法替布治疗结节性痒疹：一例报告
Clin Cosmet Investig Dermatol. 2022 Mar 21;15:503-506. doi: 10.2147/CCID.S354025. eCollection 2022.
9
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.尼莫利珠单抗治疗结节性痒疹患者的 3 期临床试验。
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
10
Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis.乌帕替尼用于治疗伴有泛发性结节性痒疹的中度至重度特应性皮炎。
Asian J Surg. 2024 Jul;47(7):3084-3088. doi: 10.1016/j.asjsur.2024.02.127. Epub 2024 Mar 6.

引用本文的文献

1
Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature.结节性痒疹治疗中的新兴疗法：生物疗法及文献系统综述
Dermatol Ther (Heidelb). 2025 May 15. doi: 10.1007/s13555-025-01437-8.
2
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review.用于治疗结节性痒疹的新型及新兴生物制剂和JAK抑制剂：一项叙述性综述
Medicina (Kaunas). 2025 Mar 29;61(4):631. doi: 10.3390/medicina61040631.